Jim Cramer Believes Marvell Technology is a Buy for 5G and AI Growth

Published 1 days agoMRVL

Jim Cramer Believes Marvell Technology is a Buy for 5G and AI Growth

Jim Cramer, the host of CNBC's 'Mad Money,' has recently given a positive nod to Marvell Technology's stock, underscoring its potential within the semiconductor industry. On the May 31, 2025 edition of 'Mad Money,' Cramer recommended buying Marvell's stock, suggesting investors make a move by the following Monday.

Cramer has spotlighted Marvell's strong positioning in the rapidly evolving 5G wireless field, dubbing it 'the ultimate 5G wireless play.' Furthermore, he pointed out the company's notable growth in AI-related revenues, which have surged from under $200 million to $1.5 billion. As per NBC New York's report, Cramer believes that the market may not have fully recognized Marvell's AI expansion.

On the market side, Marvell Technology's stock was trading at $60.19 on May 31, 2025, marking a minor dip of 5.67% from its previous close. Despite this downturn, Cramer's remarks indicate that Marvell's strategic moves in integrating 5G and AI could make it an appealing option for investors looking to capitalize on these sectors' growth.

Share this article

Twitter Facebook LinkedIn

Recent Articles

British American Tobacco Ups Sales Growth Target Amid U.S. Market Gains

British American Tobacco Ups Sales Growth Target Amid U.S. Market Gains

26 minutes agoBTI

British American Tobacco (BAT) has revised its annual sales growth target upward, now aiming for a 1% to 2% increase. This adjustment comes after better-than-expected revenue performance, particularly driven by the U.S. market. Previously set at 1%, this updated target reflects the rising contributions from BAT's key markets and strategic initiatives. Reuters reported that BAT expects to see a return to revenue and profit growth in the U.S. by 2025, with first-half revenues already trending slightly above expectations. In addition to traditional tobacco sales, BAT is seeing low single-digit revenue growth in its non-combustible product categories, such as vapes and oral nicotine pouches, reflecting a shift in consumer preferences. However, the company is navigating challenges like declining traditional tobacco sales, regulatory pressures, and the rise of cheaper and alternative products, including illegal vapes. BAT has been focusing on investments in its U.S. commercial operations and innovation across its 'New Categories' segment, which includes non-combustible products. These strategies have fueled its improved performance and align with its mid-term guidance aiming for a 3-5% revenue increase and mid-single-digit adjusted profit from operations growth by 2026. Despite industry challenges, BAT remains committed to achieving its growth objectives through continued investment and adaptation.

KKR Pulls Out of Thames Water Rescue Deal, Leaving Financial Uncertainty

KKR Pulls Out of Thames Water Rescue Deal, Leaving Financial Uncertainty

41 minutes agoKKR

KKR, a U.S. private equity firm, has decided not to move forward with a proposed investment in Thames Water, marking a significant setback for the utility company. The withdrawal is a major blow as Thames Water was counting on over £3 billion in new equity from KKR to help manage its severe financial difficulties, Reuters reported. Thames Water, which serves 16 million customers, is grappling with substantial debts and has now been left searching for alternative solutions. In light of KKR's exit, Chairman Adrian Montague expressed disappointment and indicated that the company would now focus on discussions with senior creditors who have proposed an alternative rescue plan. In the absence of a successful resolution, there is a lingering threat of temporary government nationalization. Amid these financial challenges, Thames Water is also under regulatory scrutiny due to its impact on pollution and increasing customer bills. This development aligns with an interim government review demanding reforms in the water sector, putting additional pressure on the company to stabilize its operations and address its debt obligations.

Coinbase Faces Major Data Breach Linked to India

Coinbase Faces Major Data Breach Linked to India

56 minutes agoCOIN

Coinbase has discovered a substantial data breach that originated in India, with the incident coming to light in May 2025. According to Reuters, this breach, which began in January 2025, involved a rogue employee at TaskUs, an outsourcing firm in Indore, India. The employee was found to have taken photographs of sensitive Coinbase customer data and shared them with hackers in exchange for bribes. The breach resulted in the unauthorized dissemination of personal information, including customers' names, birthdates, and partial Social Security numbers. The hackers demanded a $20 million ransom, threatening to release the information publicly unless paid. Coinbase refused to comply with the ransom demand and has instead offered a $20 million reward for information leading to those responsible. The financial impact of this breach could be significant, with potential costs ranging from $180 million to $400 million, as reported by Reuters. In response to the breach, Coinbase promptly severed ties with the involved TaskUs employee and enforced stricter security protocols to prevent future breaches. Meanwhile, the U.S. Securities and Exchange Commission (SEC) is currently probing Coinbase for possibly misstating user data, although the company maintains that it has adhered to all compliance requirements. This incident serves as a stern reminder of the vulnerabilities that persist in the cryptocurrency sector and the critical need for robust data protection strategies.

Sanofi's Rilzabrutinib Gains Orphan Drug Status for Rare Diseases

Sanofi's Rilzabrutinib Gains Orphan Drug Status for Rare Diseases

Sanofi's investigational drug rilzabrutinib has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for two rare conditions: warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD). This status is crucial for these conditions, as no approved treatments currently exist. The FDA reserves orphan drug status for therapies targeting rare diseases affecting fewer than 200,000 people in the U.S. Beyond these designations, rilzabrutinib is also under review in several regions, including the U.S., European Union, and China, for potential treatment of immune thrombocytopenia (ITP), a bleeding disorder. The FDA has set an action date of August 29, 2025, for its decision on ITP, after previously fast-tracking the drug for this condition. Clinical trials have shown encouraging signs, with a Phase 2b study for wAIHA revealing significant improvements in response rates and disease markers, while a Phase 2a study for IgG4-RD showed reduced flare-ups and reliance on glucocorticoids. Sanofi has indicated that these advancements are part of its broader strategy to focus on innovative treatments for uncommon immune disorders, fulfilling significant unmet needs in the medical community. As Reuters noted, Sanofi is actively pursuing regulatory pathways that could bring these promising therapies to patients who need them.